MX2023011014A - Inhibidores de heteroarílo de la calicreína plasmática. - Google Patents
Inhibidores de heteroarílo de la calicreína plasmática.Info
- Publication number
- MX2023011014A MX2023011014A MX2023011014A MX2023011014A MX2023011014A MX 2023011014 A MX2023011014 A MX 2023011014A MX 2023011014 A MX2023011014 A MX 2023011014A MX 2023011014 A MX2023011014 A MX 2023011014A MX 2023011014 A MX2023011014 A MX 2023011014A
- Authority
- MX
- Mexico
- Prior art keywords
- plasma kallikrein
- inhibitors
- heteroaryl inhibitors
- heteroaryl
- compositions
- Prior art date
Links
- 102000003827 Plasma Kallikrein Human genes 0.000 title abstract 2
- 108090000113 Plasma Kallikrein Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162468P | 2021-03-17 | 2021-03-17 | |
| PCT/US2022/020482 WO2022197758A1 (en) | 2021-03-17 | 2022-03-16 | Heteroaryl inhibitors of plasma kallikrein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011014A true MX2023011014A (es) | 2023-12-06 |
Family
ID=81328275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011014A MX2023011014A (es) | 2021-03-17 | 2022-03-16 | Inhibidores de heteroarílo de la calicreína plasmática. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240228488A1 (enExample) |
| EP (2) | EP4585265A3 (enExample) |
| JP (1) | JP2024516073A (enExample) |
| KR (1) | KR20240004296A (enExample) |
| CN (1) | CN117355521A (enExample) |
| AU (1) | AU2022240596A1 (enExample) |
| BR (1) | BR112023018619A2 (enExample) |
| CA (1) | CA3208243A1 (enExample) |
| MX (1) | MX2023011014A (enExample) |
| WO (1) | WO2022197758A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112135825A (zh) | 2018-03-13 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 血浆激肽释放酶抑制剂及其用途 |
| CN114728962B (zh) | 2019-09-18 | 2025-09-19 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
| WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
| WO2022197755A1 (en) * | 2021-03-17 | 2022-09-22 | Shire Human Genetic Therapies, Inc. | Imidazopyridinyl inhibitors of plasma kallikrein |
| EP4585265A3 (en) | 2021-03-17 | 2025-10-15 | Takeda Pharmaceutical Company Limited | Heteroaryl inhibitors of plasma kallikrein |
| JP2025531158A (ja) * | 2022-09-21 | 2025-09-19 | 武田薬品工業株式会社 | シクロプロパンカルボン酸の合成 |
| EP4735442A1 (en) * | 2023-06-29 | 2026-05-06 | Theranib Inc. | IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS |
| CN117069662A (zh) * | 2023-10-17 | 2023-11-17 | 峰成医药科技(天津)有限公司 | 一种4,6-二氯-2-（二氟甲基）嘧啶的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB201421088D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| US9815853B2 (en) * | 2015-06-12 | 2017-11-14 | Global Blood Therapeutics, Inc. | Bridged bicyclic kallikrein inhibitors |
| CN112135825A (zh) * | 2018-03-13 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 血浆激肽释放酶抑制剂及其用途 |
| EP4585265A3 (en) | 2021-03-17 | 2025-10-15 | Takeda Pharmaceutical Company Limited | Heteroaryl inhibitors of plasma kallikrein |
-
2022
- 2022-03-16 EP EP25179074.7A patent/EP4585265A3/en active Pending
- 2022-03-16 BR BR112023018619A patent/BR112023018619A2/pt unknown
- 2022-03-16 JP JP2023557140A patent/JP2024516073A/ja active Pending
- 2022-03-16 WO PCT/US2022/020482 patent/WO2022197758A1/en not_active Ceased
- 2022-03-16 CA CA3208243A patent/CA3208243A1/en active Pending
- 2022-03-16 AU AU2022240596A patent/AU2022240596A1/en active Pending
- 2022-03-16 US US18/550,306 patent/US20240228488A1/en active Pending
- 2022-03-16 CN CN202280022472.XA patent/CN117355521A/zh active Pending
- 2022-03-16 KR KR1020237034887A patent/KR20240004296A/ko active Pending
- 2022-03-16 MX MX2023011014A patent/MX2023011014A/es unknown
- 2022-03-16 EP EP22716137.9A patent/EP4308230A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240004296A (ko) | 2024-01-11 |
| BR112023018619A2 (pt) | 2023-11-28 |
| CA3208243A1 (en) | 2022-09-22 |
| CN117355521A (zh) | 2024-01-05 |
| EP4585265A2 (en) | 2025-07-16 |
| AU2022240596A1 (en) | 2023-10-19 |
| US20240228488A1 (en) | 2024-07-11 |
| JP2024516073A (ja) | 2024-04-12 |
| EP4585265A3 (en) | 2025-10-15 |
| EP4308230A1 (en) | 2024-01-24 |
| WO2022197758A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4477220A3 (en) | Plasma kallikrein inhibitors and uses thereof | |
| WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| EP4585265A3 (en) | Heteroaryl inhibitors of plasma kallikrein | |
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| PH12021553018A1 (en) | New egfr inhibitors | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MX2023012907A (es) | Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3). | |
| MX2021001433A (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa. | |
| MX2019012431A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| EP4302827A3 (en) | Rapamycin analogs and uses thereof | |
| ZA202304734B (en) | Alpha protein kinase 1 inhibitors and methods of use | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| EP4706394A3 (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| MX2019000884A (es) | Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton. | |
| PH12022552955A1 (en) | Non-lysosomal glucosylceramidase inhibitors and uses thereof | |
| MX2025008454A (es) | Inhibidores de mptp | |
| AU2018284249A1 (en) | Aminothiazole compounds as protein kinase inhibitors | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| PH12022552954A1 (en) | Non-lysosomal glucosylceramidase inhibitors and uses thereof | |
| WO2021249904A3 (en) | Amino-pyrimidine cyclo-amides |